Author:
Chen Xuanxin,Wang Danni,Wang Zhijian,Huang Wenxiang
Subject
Cell Biology,Molecular Biology,Biochemistry,Biophysics
Reference25 articles.
1. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis;Kiarash;Lancet Gastroenterol Hepatol.,2022
2. Resmetirom: an orally administered, smallmolecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis;Gres;touchREV Endocrinol,2023
3. Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Paul;Gastroenterology,2015
4. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up;Mattias;Hepatology,2015
5. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis;Taylor Rod;Gastroenterology,2020